Skip to content
DataLookout
Menu

NCT03178149

A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

StatusRecruiting
PhasePhase 1
Primary completion (estimated)

At risk: Primary completion moved at least 1 year 6 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 49 versions: 42 with changes below, 7 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Start date pushed from Jul 13, 2018 to Jan 30, 2019
    • Eligibility criteria shortened, about 22 words
    • Secondary endpoints: details revised at 12 of 12 entries
    • Site details revised at 2 of 20 sites
  2. Notable Primary and study completion pushed from Jun 30, 2026 to Dec 31, 2027
    • Study sites: 19 to 20
    v48
  3. Minor Study sites: 18 to 19v47
  4. Minor Site details revised at 1 of 18 sitesv46
  5. Minor Study sites: 17 to 18v45
Show 36 earlier versionsHide 36 earlier versions
  1. Minor Study sites: 16 to 17v44
  2. Minor Site details revised at 1 of 16 sitesv43
  3. Minor Study sites: 15 to 16v42
  4. Notable Eligibility criteria revisedv41
  5. Minor Study sites: 14 to 15v40
  6. Notable Eligibility criteria shortened, about 133 words
    • Secondary endpoints: 11 to 12
    v39
  7. Minor Primary and study completion dates: Jan 31, 2026 to Jun 30, 2026v38
  8. Study Status, Eligibility, IPDSharingv37
  9. Notable Eligibility criteria expanded, about 4 words
    • Study sites: 12 to 14
    v36
  10. Minor Primary and study completion dates: Dec 31, 2025 to Jan 31, 2026v35
  11. Notable Enrollment target: 18 to 42v34 Show 6 more changesShow less
    • Primary and study completion dates: Aug 31, 2024 to Dec 31, 2025
    • Eligibility criteria expanded, about 257 words
    • Interventions: ASP7317 (Drug), tacrolimus (Drug) to ASP7317 (Drug), Acyclovir (Drug), Nystatin (Drug), tacrolimus (Drug), trimethoprim-sulfamethoxazole (Drug)
    • Secondary endpoints: 4 to 11
    • Study description revised
    • Study title expanded, about 1 word
  12. Minor Site details revised at 1 of 12 sitesv33
  13. Minor Site details revised at 1 of 12 sitesv32
  14. Minor Site details revised at 1 of 12 sitesv30
  15. Minor Study sites: 11 to 12v29
  16. Minor Site details revised at 1 of 11 sitesv28
  17. Notable Trial status: Active, Not Recruiting to Recruiting
    • Primary and study completion dates: Nov 30, 2022 to Aug 31, 2024
    • Study sites: 6 to 11
    • Study description shortened, about 11 words
    v27
  18. Minor Primary and study completion dates: Nov 2022 to Nov 30, 2022
    • Study description expanded, about 2 words
    v23
  19. Notable Phase: Phase 1/2 to Phase 1v22 Show 10 more changesShow less
    • Enrollment target: 150 to 18
    • Primary and study completion dates: Jan 2027 to Nov 2022
    • Eligibility criteria shortened, about 92 words
    • Primary endpoints: 13 to 5
    • Study sites: 8 to 6
    • Interventions: ASP7317 (Drug), Placebo (Other), mycophenolate mofetil (MMF) (Drug), tacrolimus (Drug) to ASP7317 (Drug), tacrolimus (Drug)
    • Secondary endpoints: 6 to 4
    • Study description shortened, about 24 words
    • Study arms: 6 to 2
    • Study title expanded, about 2 words
  20. Minor Study sites: 10 to 8v21
  21. Notable Primary and study completion dates pushed to Jan 2027v19
  22. Minor Trial status: Recruiting to Active, Not Recruiting
    • Study description expanded, about 9 words
    • Site details revised at 10 of 10 sites
    v18
  23. Minor Study description shortened, about 315 words
    • Study title shortened, about 4 words
    v16
  24. Minor Study description expanded, about 21 wordsv15
  25. Minor Site details revised at 1 of 10 sitesv14
  26. Minor Study sites: 9 to 10v13
  27. Minor Study sites: 8 to 9v12
  28. Notable Eligibility criteria shortened, about 345 words
    • Primary endpoints revised (13)
    • Secondary endpoints: details revised at 1 of 6 entries
    v11
  29. Minor Study sites: 5 to 8v10
  30. Minor Study sites: 4 to 5v9
  31. Minor Study sites: 3 to 4v8
  32. Notable Eligibility criteria shortened, about 5 words
    • Study sites: 2 to 3
    v7
  33. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 2
    • Start date changed from estimate of Dec 2018 to Jul 13, 2018
    v6
  34. Notable Start date: Mar 2018 to Dec 2018v4
  35. Notable Eligibility criteria expanded, about 87 words
    • Primary endpoints: 6 to 13
    • Secondary endpoints: 4 to 6
    • Study description expanded, about 21 words
    v3
  36. Notable Primary completion date: Aug 31, 2020 to Apr 2021
    • Start date: Aug 21, 2017 to Mar 2018
    • Study completion date: Feb 28, 2026 to Oct 2026
    • Interventions: ASP7317 (Drug), Placebo (Other), Prograf® (Drug), mycophenolate mofetil (MMF) (Drug) to ASP7317 (Drug), Placebo (Other), mycophenolate mofetil (MMF) (Drug), tacrolimus (Drug)
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Safety as assessed by incidence, frequency and severity of treatment emergent adverse events (TEAES)
Timeframe: Up to 52 Weeks
Safety as assessed by incidence, frequency and severity of Serious Adverse Events (SAEs)
Timeframe: Up to 52 Weeks
Safety assessed by Adverse Events (AEs) of special interest
Timeframe: Up to 52 Weeks
Number of participants with cellular graft failure or rejection
Timeframe: Up to 52 Weeks
Incidence of cellular graft failure or rejection
Timeframe: Up to 52 Weeks

Secondary (12)

Mean change from baseline in area of Geographic Atrophy (GA) (mm^2) in study eye and fellow eye
Mean percent change from baseline in area of Geographic Atrophy (GA) (mm^2) in study eye and fellow eye
Mean change from baseline in the square root transformation of Geographic Atrophy (GA) area in study eye and fellow eye
Mean change from baseline in best corrected visual acuity (BCVA) score in study eye and fellow eye
Mean change from baseline in mean sensitivity
Show 7 moreShow less
Mean change from baseline in point wise sensitivity (PWS) in treatment zone
Mean change from baseline in PWS in extended treatment zone
Mean change from baseline in PWS in remote zone
Mean change from baseline in PWS in extended remote zone
Mean change from baseline in number of scotomatous points
Mean change from baseline in fixation stability (95% bivariate contour ellipse area (BCEA))
Mean change from baseline in distance of preferred retinal locus (PRL) from Fovea

Arms and interventions

ASP7317 Dose Escalation/ Expansion (Group 1: Severe Vision Loss)Experimental

Successive cohorts of participants (3 participants each) will be given escalating doses (cohort 1: low cells/dose; cohort 2: medium cells/dose; cohort 3: high cells/dose). Optional Expansion cohorts 3b will be opened after cohort 3 has been filled and 2b will be opened only if necessary. Dose levels for the expansion cohort will align with dose levels in escalation cohorts. Sentinel dosing will be required for each dose level. After the first participant in each dose cohort in Group 1 is dosed and followed for 4 weeks, the Independent Data Monitoring Committee (IDMC) will review the 4-week safety data and recommend if the second and third participants in Group 1 dose cohort may be treated. The IDMC recommendation to progress to the next dosing cohort will be based on 4-week follow-up safety review of the second and third participants in the preceding dose cohort. Participants will receive tacrolimus and other medicines to stop infection.

ASP7317 Dose Escalation/ Expansion (Group 2: Moderate Vision Loss)Experimental

Successive cohorts of participants (3 participants each) will be given escalating doses (cohort 4: low cells/dose; cohort 5: medium cells/dose; cohort 6: high cells/dose). Optional Expansion cohorts 5b and 6b will be opened after cohorts 5 and 6 have been filled. Dose levels for the expansion cohorts will align with dose levels in escalation cohorts. Cohort 4 (low cells/dose) dosing may begin after the IDMC recommendation to begin dosing in Group 1 cohort 2 (medium cells/dose). Cohort 5 (medium cells/dose) dosing may begin after IDMC review of the 4- week safety data of the first participant in Group 1 cohort 2 (medium cells/dose). Cohort 6 (high cells/dose) dosing may begin after IDMC review of 4-week safety data of the first participant in Group 1 cohort 3 (high cells/dose). Dosing in cohort 5 and 6 can only begin after the IDMC review and the completion of the preceding cohort. Participants will receive tacrolimus and other medicines to stop infection.

Drugs: ASP7317, tacrolimus, trimethoprim-sulfamethoxazole, Acyclovir, Nystatin

Sites

20 sites in 1 country